Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00021827
Status:
COMPLETED
Last Update Posted:
2010-03-02
First Post:
2001-08-04
Brief Title:
PTHrP and Osteoporosis
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Study Overview
Official Title:
Pathophysiology of PTH-related Protein in Humans
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PTH-related protein or PTHrP is a hormone which was discovered in 1987 As its name implies it is closely related to another hormone discovered in the 1920s named parathyroid hormone or PTH PTH has been shown to be effective in treating osteoporosis in both animals and humans PTHrP has been shown to be effective in treating osteoporosis in laboratory animals and there are strong scientific reasons to think that it may be effective in humans as well However no human trials with PTHrP in the treatment of osteoporosis have been performed The studies in this trial are focussed on determining whether PTHrP can indeed increase bone mass in postmenopausal women with osteoporosis when administered daily by subcutaneous injection for three months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RO-1 DK 51081 | None | None | None |